


# Identification of secondary prevention patients eligible for PCSK9 inhibitors therapy according to the routine clinical practice in Spain


Juan Cosin-Sales, Eduard Sidelnikov, Santiago Villamayor, Miriam Fernández, Sandra Merino-Montero, Alberto Zamora.

- 9,516 ASCVD patients
- 63.9% male
- Mean (SD) age 67.7 (12.5) years
- Mean LDL-C (SD) 117.3 (38.8) mg/dL

## Type of lipid-lowering therapy (LLT) used in ASCVD patients \*



## Patients eligible for PCSK9i in Spain (LDL-C >100 mg/dL) \*\*



The 17.9% of patients who are not treated with a PCSK9i despite being eligible remain at an unnecessarily excess risk of a recurrent CV event

\* Myocardial infarction, unstable angina, ischaemic stroke, transient ischaemic attack, or peripheral artery disease patients with  $\geq 1$  LDL-C measurement available in a time period  $\geq 3$  months after index date.

\*\* According to the reimbursement conditions applicable in Spain (Therapeutic Positioning Report ).

PEER-REVIEWED  
FEATURE



OPEN  
ACCESS

The graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © The authors, CC-BY-NC 2022